Carlyle Group Co-Founder And Co-Chairman David Rubenstein Joins Moderna's Board of Directors, Effective August 5, 2024 - Filing
Portfolio Pulse from Benzinga Newsdesk
David Rubenstein, Co-Founder and Co-Chairman of Carlyle Group, will join Moderna's Board of Directors effective August 5, 2024. Directors Robert Langer and Stephen Berenson will retire from the Board.
July 23, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
David Rubenstein, Co-Founder and Co-Chairman of Carlyle Group, will join Moderna's Board of Directors. This move could enhance Carlyle Group's influence and network in the biotech sector.
David Rubenstein's new role at Moderna could strengthen Carlyle Group's position and network in the biotech industry, potentially leading to new opportunities and partnerships.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
David Rubenstein will join Moderna's Board of Directors, while Robert Langer and Stephen Berenson will retire. Rubenstein's extensive experience could bring new strategic insights to Moderna.
David Rubenstein's appointment to Moderna's Board could provide valuable strategic insights and enhance the company's governance, potentially leading to positive developments for Moderna.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100